Cancer Biomarkers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
The Global Cancer Biomarkers Market was valued at USD 27.5 billion in 2024 and is projected to grow at a CAGR of 12.4% between 2025 and 2034. Cancer biomarkers, which comprise proteins, genes, and various molecules found in blood, tissues, and bodily fluids, are becoming essential tools in modern oncology. As cancer prevalence continues to surge worldwide, these biomarkers are revolutionizing the way healthcare professionals detect, monitor, and treat different forms of cancer. They play a pivotal role in diagnosing cancer at an early stage, evaluating disease progression, and tailoring personalized therapies, ultimately enhancing patient survival rates and quality of life. The growing emphasis on precision medicine and targeted therapies is further driving demand for advanced biomarker technologies, as healthcare systems strive to improve diagnostic accuracy while reducing unnecessary treatments.
Ongoing research and innovation in molecular diagnostics are also expanding the scope of biomarkers, making them indispensable in clinical trials, drug development, and treatment monitoring. With cancer being one of the leading causes of death globally, the integration of biomarkers into routine clinical practice is gaining momentum, as they hold immense promise in identifying cancer even before symptoms arise, thereby enabling early interventions and better outcomes. Moreover, the continuous improvements in liquid biopsy, genomic analysis, and proteomics are broadening the potential applications of cancer biomarkers, offering new avenues for non-invasive and highly accurate cancer detection solutions.
The instruments segment in the cancer biomarker detection market generated USD 11.7 billion in 2024 and is anticipated to grow at a CAGR of 12.3% from 2025 to 2034. Advanced diagnostic tools such as polymerase chain reaction (PCR) machines, next-generation sequencing (NGS) platforms, and mass spectrometers are at the forefront of cancer biomarker research. These instruments offer unmatched sensitivity and precision in detecting genetic mutations and molecular signatures associated with cancer. They also support multiplexing, which allows simultaneous analysis of multiple biomarkers in a single test, significantly improving efficiency and cost-effectiveness. The integration of cutting-edge technologies in these instruments ensures faster diagnosis, enhanced reliability, and broader accessibility, making them critical to the expanding cancer biomarkers landscape.
The market is segmented based on cancer types, including breast, prostate, colorectal, cervical, liver, and lung cancers. The breast cancer segment accounted for a dominant share of 28.6% in 2024 and is forecasted to reach USD 25.9 billion by 2034. Biomarkers are fundamental in detecting breast cancer at an early stage, with tests like CA 15-3 and CA 27-29 serving as important tools to improve diagnostic precision when used alongside traditional imaging methods. The continuously rising incidence of breast cancer globally and increasing awareness about early screening methods are key contributors to the growth of this segment.
The U.S. Cancer Biomarkers Market generated USD 9.2 billion in 2023, positioning itself as one of the leading regional markets worldwide. The surging cancer rates across the country, combined with advancements in biomarker-based diagnostic solutions, are driving robust market growth. Increasing demand for early detection and personalized medicine continues to make the U.S. a significant hub for cancer biomarker research and innovation.
Ongoing research and innovation in molecular diagnostics are also expanding the scope of biomarkers, making them indispensable in clinical trials, drug development, and treatment monitoring. With cancer being one of the leading causes of death globally, the integration of biomarkers into routine clinical practice is gaining momentum, as they hold immense promise in identifying cancer even before symptoms arise, thereby enabling early interventions and better outcomes. Moreover, the continuous improvements in liquid biopsy, genomic analysis, and proteomics are broadening the potential applications of cancer biomarkers, offering new avenues for non-invasive and highly accurate cancer detection solutions.
The instruments segment in the cancer biomarker detection market generated USD 11.7 billion in 2024 and is anticipated to grow at a CAGR of 12.3% from 2025 to 2034. Advanced diagnostic tools such as polymerase chain reaction (PCR) machines, next-generation sequencing (NGS) platforms, and mass spectrometers are at the forefront of cancer biomarker research. These instruments offer unmatched sensitivity and precision in detecting genetic mutations and molecular signatures associated with cancer. They also support multiplexing, which allows simultaneous analysis of multiple biomarkers in a single test, significantly improving efficiency and cost-effectiveness. The integration of cutting-edge technologies in these instruments ensures faster diagnosis, enhanced reliability, and broader accessibility, making them critical to the expanding cancer biomarkers landscape.
The market is segmented based on cancer types, including breast, prostate, colorectal, cervical, liver, and lung cancers. The breast cancer segment accounted for a dominant share of 28.6% in 2024 and is forecasted to reach USD 25.9 billion by 2034. Biomarkers are fundamental in detecting breast cancer at an early stage, with tests like CA 15-3 and CA 27-29 serving as important tools to improve diagnostic precision when used alongside traditional imaging methods. The continuously rising incidence of breast cancer globally and increasing awareness about early screening methods are key contributors to the growth of this segment.
The U.S. Cancer Biomarkers Market generated USD 9.2 billion in 2023, positioning itself as one of the leading regional markets worldwide. The surging cancer rates across the country, combined with advancements in biomarker-based diagnostic solutions, are driving robust market growth. Increasing demand for early detection and personalized medicine continues to make the U.S. a significant hub for cancer biomarker research and innovation.
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market scope and definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of cancer
3.2.1.2 Advancements in personalized medicine
3.2.1.3 Technological advancements in diagnostic tools
3.2.1.4 Increasing research and development activities
3.2.2 Industry pitfalls and challenges
3.2.2.1 High costs of biomarker development and testing
3.2.2.2 Lack of standardization
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Future market trends
3.7 Porter’s analysis
3.8 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2024
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PRODUCT, 2021 – 2034 ($ MN)
5.1 Key trends
5.2 Instruments
5.3 Consumables
5.4 Software
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY CANCER TYPE, 2021 – 2034 ($ MN)
6.1 Key trends
6.2 Breast cancer
6.3 Prostate cancer
6.4 Colorectal cancer
6.5 Cervical cancer
6.6 Liver cancer
6.7 Lung cancer
6.8 Other cancer types
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 – 2034 ($ MN)
7.1 Key trends
7.2 Drug discovery and development
7.3 Diagnostics
7.4 Personalized medicine
7.5 Other applications
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY TECHNOLOGY, 2021 – 2034 ($ MN)
8.1 Key trends
8.2 OMICS technologies
8.2.1 Proteomics
8.2.2 Genomics
8.2.3 Other OMICS technologies
8.3 Imaging technologies
8.3.1 Ultrasound
8.3.2 Computed tomography
8.3.3 Magnetic resonance imaging
8.3.4 Positron emission tomography
8.3.5 Mammography
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 – 2034 ($ MN)
9.1 Key trends
9.2 Hospitals
9.3 Diagnostic laboratories
9.4 Biopharmaceutical companies
9.5 Academic and research institutions
9.6 Other end use
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 ($ MN)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
CHAPTER 11 COMPANY PROFILES
11.1 Abbott Laboratories
11.2 Agilent Technologies
11.3 Bio-Rad Laboratories
11.4 Becton, Dickinson and Company
11.5 BioGenex
11.6 Centogene
11.7 F. Hoffmann-La Roche
11.8 Hologic
11.9 INOVIQ
11.10 Illumina
11.11 Merck & Co.
11.12 QIAGEN
11.13 Sino Biological
11.14 Sysmex Corporation
11.15 Thermo Fisher Scientific
1.1 Market scope and definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of cancer
3.2.1.2 Advancements in personalized medicine
3.2.1.3 Technological advancements in diagnostic tools
3.2.1.4 Increasing research and development activities
3.2.2 Industry pitfalls and challenges
3.2.2.1 High costs of biomarker development and testing
3.2.2.2 Lack of standardization
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Future market trends
3.7 Porter’s analysis
3.8 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2024
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PRODUCT, 2021 – 2034 ($ MN)
5.1 Key trends
5.2 Instruments
5.3 Consumables
5.4 Software
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY CANCER TYPE, 2021 – 2034 ($ MN)
6.1 Key trends
6.2 Breast cancer
6.3 Prostate cancer
6.4 Colorectal cancer
6.5 Cervical cancer
6.6 Liver cancer
6.7 Lung cancer
6.8 Other cancer types
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 – 2034 ($ MN)
7.1 Key trends
7.2 Drug discovery and development
7.3 Diagnostics
7.4 Personalized medicine
7.5 Other applications
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY TECHNOLOGY, 2021 – 2034 ($ MN)
8.1 Key trends
8.2 OMICS technologies
8.2.1 Proteomics
8.2.2 Genomics
8.2.3 Other OMICS technologies
8.3 Imaging technologies
8.3.1 Ultrasound
8.3.2 Computed tomography
8.3.3 Magnetic resonance imaging
8.3.4 Positron emission tomography
8.3.5 Mammography
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 – 2034 ($ MN)
9.1 Key trends
9.2 Hospitals
9.3 Diagnostic laboratories
9.4 Biopharmaceutical companies
9.5 Academic and research institutions
9.6 Other end use
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 ($ MN)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
CHAPTER 11 COMPANY PROFILES
11.1 Abbott Laboratories
11.2 Agilent Technologies
11.3 Bio-Rad Laboratories
11.4 Becton, Dickinson and Company
11.5 BioGenex
11.6 Centogene
11.7 F. Hoffmann-La Roche
11.8 Hologic
11.9 INOVIQ
11.10 Illumina
11.11 Merck & Co.
11.12 QIAGEN
11.13 Sino Biological
11.14 Sysmex Corporation
11.15 Thermo Fisher Scientific
